Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by First Eagle Investment Management LLC

First Eagle Investment Management LLC reduced its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 50.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,081 shares of the company's stock after selling 104,551 shares during the quarter. First Eagle Investment Management LLC owned about 0.22% of Pacira BioSciences worth $3,478,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PCRX. Nisa Investment Advisors LLC boosted its position in shares of Pacira BioSciences by 310.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company's stock valued at $61,000 after purchasing an additional 1,514 shares during the period. Quadrant Capital Group LLC grew its position in Pacira BioSciences by 61.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company's stock worth $78,000 after purchasing an additional 885 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Pacira BioSciences by 63.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,481 shares of the company's stock worth $137,000 after purchasing an additional 1,736 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Pacira BioSciences by 9.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company's stock valued at $157,000 after purchasing an additional 438 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Pacira BioSciences by 353.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,373 shares of the company's stock valued at $181,000 after buying an additional 4,188 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Price Performance

PCRX stock traded down $0.69 during trading on Friday, reaching $30.82. 478,755 shares of the company were exchanged, compared to its average volume of 981,805. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.78 and a current ratio of 5.81. The stock's 50 day moving average price is $28.34 and its 200 day moving average price is $29.63. Pacira BioSciences, Inc. has a 52-week low of $25.33 and a 52-week high of $42.63. The company has a market cap of $1.43 billion, a P/E ratio of 21.55 and a beta of 0.77.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, hitting the consensus estimate of $0.71. Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. The business had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. As a group, analysts predict that Pacira BioSciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PCRX shares. Royal Bank of Canada dropped their price target on Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating on the stock in a research report on Friday, March 1st. Wedbush restated an "outperform" rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Thursday, February 8th. JPMorgan Chase & Co. began coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They issued an "overweight" rating and a $45.00 price objective on the stock. TheStreet upgraded shares of Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. Finally, HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Pacira BioSciences in a research note on Wednesday, May 8th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of "Buy" and a consensus price target of $47.40.

Insider Activity

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the firm's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares in the company, valued at approximately $4,165,193.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Gary W. Pace sold 90,000 shares of the company's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gary W. Pace sold 1,066 shares of the firm's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the sale, the director now directly owns 140,384 shares in the company, valued at $4,165,193.28. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.